Today is world MS day #bringinguscloser

I'm thrilled to welcome Ian J. Reynolds as CEO of Rewind Therapeutics. Ian is a smart, passionate and extremely talented drug-hunter in the world of neuroscience. He has a strong and deep track record of novel drug development.

Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer

Biotechmecenas Mariën opent nieuwe Gentse biotechcampus tijd.be/r/t/1/id/10057…

Rewind Therapeutics builds Scientific Advisory Board to accelerate its development of new therapies for myelin-related diseases prn.to/2A2dvsd

Rewind Therapeutics builds Scientific Advisory Board to accelerate its development of new therapies for myelin-related diseases

Very happy to welcome world leading experts Prof Brück, Prof Comi and Dr Wang to Rewind Therapeutics SAB

Our CEO will be at ECTRIMS 2018. Let’s talk!

We’re here, so let’s meet up when you want to know more about remyelination and Rewind’s approach. #BIOEurope

België is bij de wereldtop in medische biotechnologie. De Tijd brengt het hele ecosysteem in kaart. multimedia.tijd.be/biotechrevolut…

Biotech, de mirakeloplossing? Leuvense start-up vecht tegen superbacteriën tijd.be/r/t/1/id/10077…

Our CEO Ian Reynolds will be presenting today at 4.00 pm (Room Vivaldi 1) at the #BioEquity meeting in Barcelona. See you there!

This looks exciting! Congratulations to Rewind Therapeutics awarded almost €3million in an innovative collaboration to develop drug screening assays with #Human stem cell models and devise chip-based studies for nerve myelination studies TEST waguri imec rewindtherapeutics.com/news/rewind-th…

Rewind Therapeutics appoints Kees Been as Non-Executive Director prnewswire.com/news-releases/… Rewind Therapeutics More Benelux life science business news at [LSBNL] at life-sciences-benelux.com/news/vlfm-iito…

Very happy to welcome industry veteran Kees Been to our Board of Directors

Rewind Therapeutics appoints Biopharmaceutical Industry Veteran Kees Been as Non-Executive Director. bit.ly/34Xnfnl

Rewind Therapeutics, which is developing innovative first-in-class #remyelinating therapies for #myelin-related diseases such as #multiplesclerosis, appoints industry veteran Kees Been as a Non-Executive Director bit.ly/2ESVeCC

Proud to announce that our Executive Chairman Jim Van heusden will be presenting at the 21st #BioEquity Europe Global Digital event next week (17-19 May), hosted by BioCentury and EBD Group. Jim's presentation is under the “Next Wave Track”. Check it out! conferences.biocentury.com/bioequity-euro…

We have some very exciting news to share with you on this Wednesday morning! Rewind Therapeutics has selected Dr. Anja Harmeier to join us as our new CEO. We look forward to a successful journey with her. Welcome on board! See the full press release here: bit.ly/3nTmBRl

We warmly welcome our new Chief Scientific Officer Dr. Irene Knuesel. Irene has an outstanding track record in neuroimmunology and neurodegeneration and we look forward to working with her! rwdtx.com/font-face-font…